The U.S. Food and Drug Administration (USFDA) inspected
Ajanta Pharma’s Paithan manufacturing facility (Maharashtra, India) during
April 13-21, 2026. The inspection concluded with issuance of a Form 483
containing 5 observations.
• Product Profile: Total 31 products are
manufactured at this facility; 1 product is currently discontinued, and 11
products have backup manufacturing facilities.
• Revenue Contribution: The facility
contributes ~70% of Ajanta’s total US sales*, making it a highly critical site
for the company’s US generics business.
• Backup Coverage: A significant portion
of US revenue is supported by alternate manufacturing sites (Dahej facility).
• Net Exposure: However, dependency on
Paithan facility is still meaningful.
• Regulatory Context: Issuance of 5 Form
483 observations indicates compliance gaps requiring remediation; final FDA
classification (NAI/VAI/OAI) is pending. Prior NAI status on 03-05-2024 suggests
historically strong compliance.
• Products Likely Exposed to Shortages: (Based
on Sales> $3Mn, Market Share> 20% & No Backup manufacturing): We
expect 5 products exposed to likely shortages in case the FDA action escalates.
• Financial Impact: While overall exposure
is partially mitigated by strong backup coverage, product-level risk
remains elevated for high-market-share drugs without alternate
manufacturing, creating potential for supply disruption and competitor
opportunity.
If observations are addressed within standard remediation
timelines, impact is expected to remain contained. However, escalation to OAI
classification or regulatory actions (e.g., Warning Letter/import alert) could
increase risk for the exposed portfolio and lead to market share
erosion in key drugs.